An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)

Trial Profile

An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Insulin (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Pharmacodynamics
  • Sponsors Oramed Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2017 According to an Oramed Pharmaceuticals media release, Israel's Ministry of Health has granted approval to initiate this study, and company plans to initiate this study in the coming month.
    • 25 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Sep 2017.
    • 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top